RecruitingPhase 1NCT07205159

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Forte Biosciences, Inc.
Intervention
FB102(drug)
Enrollment
32 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07205159 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials